Promising inhibitor combination for hard-to-treat leukemia subtypes
Researchers from Penn Vet and other institutions have identified a novel inhibitor combination of molecules that induce terminal differentiation for the treatment of human non-APL subtypes of AML.
2 min. read
In a new study co-authored by assistant professor of biomedical sciences at Penn’s School of Veterinary Medicine M. Andrés Blanco, along with investigators from the Universities of Oxford, Helsinki, and California at San Diego, researchers have identified a promising strategy to overcome treatment resistance in acute myeloid luekemia (AML), one of the most aggressive forms of blood cancer.
Andrés Blanco is an assistant professor of biomedical science at Penn’s School of Veterinary Medicine.
(Image: John Donges)
AML occurs when bone marrow produces substantial amounts of abnormal white blood cells. Differentiation therapy, a cancer treatment that prompts cancer cells to become less aggressive thereby reducing or stopping their proliferation, is curative for the acute promyelocytic leukemia (APL) subtype of AML, but not for the other eight non-APL subtypes.
The novel inhibitor combination of histone demethylase LSD1 and glycogen synthase kinase 3 (GSK-3) induce terminal differentiation for the treatment of human non-APL subtypes of AML.
“These findings present a potential new avenue for differentiation therapy in AML subtypes that have resisted such approaches,” says Blanco. “This study provides a compelling rationale for testing dual LSD1 and GSK-3 inhibition as a therapeutic technique for humans with non-APL AML subtypes, offering hope for better outcomes with this disease.”
Penn physicists led by Bo Zhen have created hybrid light-matter particles that interact strongly enough to compute, pointing toward ultrafast, low-energy optical AI hardware.
Penn’s newest supercomputer is transforming research
Penn’s first campus-wide HPC and AI cluster, “Betty,” is expanding access to powerful computing, enabling groundbreaking projects, and fostering new collaborations across disciplines.
A bioengineered bean gum from the lab of Penn Dental’s Henry Daniell is found to reduce the levels of three microbes associated with head and neck squamous cell cancer to almost zero, without affecting the beneficial bacteria normally found in the mouth.
Fighting oral cancer with bioengineered chewing gum
Research led by Penn Dental’s Henry Daniell shows that antiviral and antibacterial chewing gums reduce the levels of three microbes linked to worse outcomes in oral cancers, paving the way for more effective and affordable therapies.
The performing arts at Penn: Process, practice, and purpose
In the vivid tapestry of performing arts groups at Penn, students prepare for their performances while simultaneously enriching their college experience.
